Literature DB >> 7553646

Significance of chromosome 1p loss of heterozygosity in neuroblastoma.

J M Maris1, P S White, C P Beltinger, E P Sulman, R P Castleberry, J J Shuster, A T Look, G M Brodeur.   

Abstract

We analyzed 156 primary neuroblastoma tumor samples for loss of heterozygosity at the distal short arm of chromosome 1 (1p LOH). We also compared 1p LOH with known clinical and genetic prognostic variables as well as patient outcome. 1p LOH was detected in 30 of 156 tumors (19%) and was strongly associated with adverse clinical and biological features. 1p LOH was also strongly predictive of a poor outcome in univariate analyses (estimated 4-year survival, 32 +/- 10% SE versus 76 +/- 5% SE; P < 0.001). However, the prognostic value of 1p LOH was equivocal when stratified for amplification of the MYCN oncogene (P = 0.16). We conclude that 1p LOH is an important component of a pattern of genetic abnormalities in neuroblastoma associated with an aggressive clinical course.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553646

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Diagnosis and classification of the small round-cell tumors of childhood.

Authors:  S L Cohn
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

2.  Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines.

Authors:  X T Kong; V A Valentine; S T Rowe; M B Valentine; S T Ragsdale; B G Jones; D A Wilkinson; G M Brodeur; S L Cohn; A T Look
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

Review 3.  Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p.

Authors:  J Mora; N K Cheung; B H Kushner; M P LaQuaglia; K Kramer; M Fazzari; G Heller; L Chen; W L Gerald
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

4.  Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36.

Authors:  M Gibbs; J L Stanford; R A McIndoe; G P Jarvik; S Kolb; E L Goode; L Chakrabarti; E F Schuster; V A Buckley; E L Miller; S Brandzel; S Li; L Hood; E A Ostrander
Journal:  Am J Hum Genet       Date:  1999-03       Impact factor: 11.025

5.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Authors:  David L Baker; Mary L Schmidt; Susan L Cohn; John M Maris; Wendy B London; Allen Buxton; Daniel Stram; Robert P Castleberry; Hiroyuki Shimada; Anthony Sandler; Robert C Shamberger; A Thomas Look; C Patrick Reynolds; Robert C Seeger; Katherine K Matthay
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

6.  Knowing your ABCCs: novel functions of ABCC transporters.

Authors:  Garrett M Brodeur
Journal:  J Natl Cancer Inst       Date:  2011-07-28       Impact factor: 13.506

7.  The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.

Authors:  Venkatadri Kolla; Koumudi Naraparaju; Tiangang Zhuang; Mayumi Higashi; Sriharsha Kolla; Gerd A Blobel; Garrett M Brodeur
Journal:  Biochem J       Date:  2015-06-01       Impact factor: 3.857

Review 8.  Role of CHD5 in human cancers: 10 years later.

Authors:  Venkatadri Kolla; Tiangang Zhuang; Mayumi Higashi; Koumudi Naraparaju; Garrett M Brodeur
Journal:  Cancer Res       Date:  2014-01-13       Impact factor: 12.701

9.  A novel 1p36.2 located gene, APITD1, with tumour-suppressive properties and a putative p53-binding domain, shows low expression in neuroblastoma tumours.

Authors:  C Krona; K Ejeskär; H Carén; F Abel; R-M Sjöberg; T Martinsson
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

10.  Lysosomal-associated protein multispanning transmembrane 5 gene (LAPTM5) is associated with spontaneous regression of neuroblastomas.

Authors:  Jun Inoue; Akiko Misawa; Yukichi Tanaka; Shizuko Ichinose; Yuriko Sugino; Hajime Hosoi; Tohru Sugimoto; Issei Imoto; Johji Inazawa
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.